Literature DB >> 27549391

Diagnostic Criteria, Classification and Treatment Goals in Multiple Sclerosis: The Chronicles of Time and Space.

Achilles Ntranos1, Fred Lublin2,3.   

Abstract

Multiple sclerosis (MS) is one of the most diverse human diseases. Since its first description by Charcot in the nineteenth century, the diagnostic criteria, clinical course classification, and treatment goals for MS have been constantly revised and updated to improve diagnostic accuracy, physician communication, and clinical trial design. These changes have improved the clinical outcomes and quality of life for patients with the disease. Recent technological and research breakthroughs will almost certainly further change how we diagnose, classify, and treat MS in the future. In this review, we summarize the key events in the history of MS, explain the reasoning behind the current criteria for MS diagnosis, classification, and treatment, and provide suggestions for further improvements that will keep enhancing the clinical practice of MS.

Entities:  

Keywords:  Clinical decision-making; Early diagnosis; History; Multiple sclerosis; Patient care; Therapeutics

Mesh:

Year:  2016        PMID: 27549391     DOI: 10.1007/s11910-016-0688-8

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  47 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

Review 2.  Radiologically isolated syndrome--incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review.

Authors:  Tobias Granberg; Juha Martola; Maria Kristoffersen-Wiberg; Peter Aspelin; Sten Fredrikson
Journal:  Mult Scler       Date:  2012-07-03       Impact factor: 6.312

3.  Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis.

Authors:  M Filippi; M A Rocca; M Calabrese; M P Sormani; F Rinaldi; P Perini; G Comi; P Gallo
Journal:  Neurology       Date:  2010-11-30       Impact factor: 9.910

4.  Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?

Authors:  Carolyn J Bevan; Bruce A C Cree
Journal:  JAMA Neurol       Date:  2014-03       Impact factor: 18.302

Review 5.  Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis.

Authors:  Amer Awad; Bernhard Hemmer; Hans-Peter Hartung; Bernd Kieseier; Jeffrey L Bennett; Olaf Stuve
Journal:  J Neuroimmunol       Date:  2009-09-25       Impact factor: 3.478

6.  Multiple sclerosis: can retinal imaging accurately detect optic neuritis?

Authors:  Elliot M Frohman; Laura J Balcer; Peter A Calabresi
Journal:  Nat Rev Neurol       Date:  2010-03       Impact factor: 42.937

7.  Aspects on classification methods in multiple sclerosis.

Authors:  T Broman; L Bergmann; T Fog; O Gilland; K Hyllested; A M Lindberg-Broman; E Pedersen; J Presthus
Journal:  Acta Neurol Scand Suppl       Date:  1965

Review 8.  Neuronal damage in brain inflammation.

Authors:  Orhan Aktas; Oliver Ullrich; Carmen Infante-Duarte; Robert Nitsch; Frauke Zipp
Journal:  Arch Neurol       Date:  2007-02

9.  Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.

Authors:  Eva Havrdova; Steven Galetta; Michael Hutchinson; Dusan Stefoski; David Bates; Chris H Polman; Paul W O'Connor; Gavin Giovannoni; J Theodore Phillips; Fred D Lublin; Amy Pace; Richard Kim; Robert Hyde
Journal:  Lancet Neurol       Date:  2009-02-07       Impact factor: 44.182

10.  Phase-Sensitive Inversion-Recovery MRI Improves Longitudinal Cortical Lesion Detection in Progressive MS.

Authors:  Asaff Harel; Antonia Ceccarelli; Colleen Farrell; Michelle Fabian; Jonathan Howard; Claire Riley; Aaron Miller; Fred Lublin; Matilde Inglese
Journal:  PLoS One       Date:  2016-03-22       Impact factor: 3.240

View more
  6 in total

1.  Association of rs12487066, rs12044852, rs10735781, rs3135388, rs6897932, rs1321172, rs10492972, and rs9657904 Polymorphisms with Multiple Sclerosis in Iranian Population.

Authors:  Takavar Razavian; Mahdieh Ebrahimi Shakib; Kurosh Gharagozli; Hossein Maghsoudi; Seyed Kazem Bidoki; Soha Sadeghi; Massoud Houshmand
Journal:  Oman Med J       Date:  2020-07-20

2.  Orthodontic treatment for a patient with multiple sclerosis.

Authors:  Manal A Bakathir
Journal:  J Orthod Sci       Date:  2017 Jul-Sep

Review 3.  Glia maturation factor-β: a potential therapeutic target in neurodegeneration and neuroinflammation.

Authors:  Junsheng Fan; Tszhei Fong; Xinjie Chen; Chuyun Chen; Peng Luo; Haiting Xie
Journal:  Neuropsychiatr Dis Treat       Date:  2018-02-09       Impact factor: 2.570

Review 4.  Platelets in Multiple Sclerosis: Early and Central Mediators of Inflammation and Neurodegeneration and Attractive Targets for Molecular Imaging and Site-Directed Therapy.

Authors:  Jacqueline M Orian; Claretta S D'Souza; Pece Kocovski; Guy Krippner; Matthew W Hale; Xiaowei Wang; Karlheinz Peter
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

5.  Do Hungarian multiple sclerosis care units fulfil international criteria?

Authors:  Zsófia Kokas; Dániel Sandi; Zsanett Fricska-Nagy; Judit Füvesi; Tamás Biernacki; Ágnes Köves; Ferenc Fazekas; Adrienne Jóri Birkás; Gabriella Katona; Krisztina Kovács; Dániel Milanovich; Enikő Dobos; István Kapás; Gábor Jakab; Tünde Csépány; Erzsébet Bense; Klotild Mátyás; Gábor Rum; Zoltán Szolnoki; István Deme; Zita Jobbágy; Dávid Kriston; Zsuzsanna Gerócs; Péter Diószeghy; László Bors; Adrián Varga; Levente Kerényi; Gabriella Molnár; Piroska Kristóf; Zsuzsanna Ágnes Nagy; Mária Sátori; Piroska Imre; Szilvia Péntek; Péter Klivényi; Zsigmond Tamás Kincses; László Vécsei; Krisztina Bencsik
Journal:  PLoS One       Date:  2022-03-03       Impact factor: 3.240

Review 6.  Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS).

Authors:  Amnon A Berger; Emily R Sottosanti; Ariel Winnick; Jonathan Izygon; Kevin Berardino; Elyse M Cornett; Alan D Kaye; Giustino Varrassi; Omar Viswanath; Ivan Urits
Journal:  Neurol Int       Date:  2021-05-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.